TodayIR: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
(2) DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prio...
Source: finanznachrichten.de